SANUWAVE Health Inc. Reports Record Q2 2025 Revenue, Up 41-42% from Q2 2024

Reuters
15 Jul
<a href="https://laohu8.com/S/SNWV">SANUWAVE Health</a> Inc. Reports Record <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue, Up 41-42% from Q2 2024

SANUWAVE Health Inc. has announced preliminary revenue results for the second quarter of 2025, indicating a range of $10.1 million to $10.2 million. This marks the highest Q2 quarterly revenues in the company's history and represents a significant increase of 41% to 42% compared to the same period in 2024. Additionally, the first half of 2025 saw revenue growth of 50-51% compared to the first half of 2024. The company attributes this revenue growth to a period of significant transition, including the addition of a new head of sales and a new head of commercial operations. SANUWAVE has rapidly expanded its sales force, reaching 13 salespeople and covering all national sales territories for the first time under CEO Morgan Frank's leadership. A key national accounts manager, dubbed the "elephant hunter," has also been added to target larger market opportunities. The company plans to release its full Q2 results on or around August 8, 2025, providing a more comprehensive update on its performance and future plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SANUWAVE Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9493257-en) on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10